**GSTM1 and GSTT1 Null Polymorphisms and Childhood Acute Leukemia Risk: Evidence from 26 Case-Control Studies**

Qiuqin Tang1*, Jing Li2,3,4,*, Simin Zhang1*, Beilei Yuan2,3, Hong Sun2, Di Wu2,3, Chuncheng Lu2,3, Wei Wu2,3,*, Yankai Xia2,3, Hongjuan Ding1, Lingqing Hu6, Daozhen Chen6,*, Jiahao Sha2,*, Xinru Wang2,3

1 State Key Laboratory of Reproductive Medicine, Department of Obstetrics, Nanjing Maternity and Child Health Care Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu, China, 2 State Key Laboratory of Reproductive Medicine, Institute of Toxicology, Nanjing Medical University, Nanjing, Jiangsu, China, 3 Key Laboratory of Modern Toxicology of Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, China, 4 Department of Public Health, Xuzhou Medical College, Xuzhou, Jiangsu, China, 5 Department of Microbial and Molecular Systems, Leuven, Belgium, 6 State Key Laboratory of Reproductive Medicine, Wuxi Maternity and Child Health Care Hospital Affiliated to Nanjing Medical University, Wuxi, Jiangsu, China

**Abstract**

Several molecular epidemiological studies have been conducted to examine the association between glutathione S-transferase mu-1 (GSTM1) and glutathione S-transferase theta-1 (GSTT1) null polymorphisms and childhood acute leukemia; however, the conclusions remain controversial. We performed an extensive meta-analysis on 26 published case-control studies with a total of 3252 cases and 5024 controls. Crude odds ratios (ORs) with 95% confidence interval were used to assess the strength of association between childhood acute leukemia risk and polymorphisms of GSTM1 and GSTT1. With respect to GSTM1 polymorphism, significantly increased risk of childhood acute leukemia was observed in the overall analysis (OR = 1.30; 95%CI, 1.11-1.51). Furthermore, a stratification analysis showed that the risk of GSTM1 polymorphism are associated with childhood acute leukemia in group of Asians (OR = 1.94; 95%CI, 1.53-2.46), Blacks (OR = 1.76; 95%CI, 1.07-2.91), ALL (OR = 1.33; 95%CI, 1.13-1.58), <100 cases and <100 controls (OR = 1.79; 95%CI, 1.21-2.64), ≥100 cases and ≥100 controls (OR = 1.25; 95%CI, 1.02-1.52), and population-based control source (OR = 1.40; 95%CI, 1.15-1.69). With respect to GSTT1 polymorphism, significant association with childhood acute leukemia risk was only found in subgroup of Asian. This meta-analysis supports that GSTM1 null polymorphism is capable of causing childhood acute leukemia susceptibility.

**Introduction**

Leukemia is the most common form of cancer in childhood accounting for approximately one third of all childhood cancers [1]; which is a heterogeneous disease lacking a high penetrant germ line-inherited predisposition, except for rare cases with genetic instability or immunodeficiency syndromes. Although overall long-term disease-free survival has been improved to higher than 70% with modern chemotherapy [2], the etiology of this disease remains unknown due to the probable multifactorial mechanisms of pathogenesis. However, molecular epidemiologic case-control studies suggest that children harboring null genotype of the glutathione S-transferase mu-1 (GSTM1) and glutathione S-transferase theta-1 (GSTT1) genes might have an increased risk of the development of childhood acute leukemia.

The GSTM1 and GSTT1 are phase II metabolic enzymes have the ability to detoxify a wide variety of electrophilic compounds including the activated carcinogens. Human glutathione S-transferases are divided into eight distinct classes as alpha, kappa, mu, omega, pi, sigma, theta, and zeta based on amino acid sequence similarity and antibody cross-reactivity [3,4]. The mu class of GSTs, encoded by the GSTM1 gene, is found on the chromosome 1p13.3 [5]. The theta class...
of GSTs, encoded by the GSTT1 gene, is located on the chromosome 22q11.23 [6]. Homozygotes for null alleles (deletion) of GSTM1 and GSTT1 have absent activity of the respective enzyme. DNA-adduct formation and rates of somatic mutation have been reported to be increased in carriers of null alleles [7]. Individuals with homozygous deletion polymorphism are considered to be at increased risk for malignancies due to reduced efficiency in protection against environmental carcinogens [8,9]. An increased frequency of GSTM1 and GSTT1 null genotypes has been associated with several types of malignancies, including stomach cancer [10], lung cancer [11], pituitary adenomas [12], bladder cancer [13], prostate cancer [14], cervical cancer [15], and acute leukemia [16].

GST polymorphisms were first reported as risk factors for childhood acute leukemia in 1997 [17]. Since then, a number of molecular epidemiological studies have been conducted to examine the association between polymorphisms within the GSTM1, GSTT1 gene and childhood acute leukemia in diverse populations [18–33]. However, the results were inconsistent or even contradictory (Table 1 and Table 2). Individual studies are typically underpowered to detect associations with GSTM1 and GSTT1 of small effect sizes. To estimate the effect of GSTM1 and GSTT1 polymorphisms on the childhood acute leukemia, as well as to quantify the potential between-study heterogeneity, we conducted a meta-analysis on 26 published case-control studies with a total of 3252 cases and 5024 controls.

Materials and Methods

1. Selection of published studies
Studies addressing the association between polymorphisms of GSTM1 and GSTT1 and the risk of childhood acute leukemia were identified by searching for articles in the PubMed and Chinese Biomedical Literature Database until 1 March 2013. Various combinations of the search terms ‘(GSTM1 or GSTT1) and (polymorphism or polymorphisms) and childhood acute leukemia’ were used to screen for potentially relevant studies. Additional articles were also checked using the references cited in these publications. Articles that had data on the different types of childhood acute leukemia (e.g., acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and acute non-lymphoblastic leukemia (ANLL)) or different ethnic groups (e.g., Asians, Blacks and Whites) were treated as independent studies. Studies included in our meta-analysis had to meet all of the following criteria: (i) studied on human beings; (ii) in a case-control study design; and (iii) had detailed genotype frequency of cases and controls or could be calculated from the article text. In current study, data for meta-analysis were available from 17 articles (26 independent case-control studies), including 3252 cases and 5024 controls.

2. Data extraction
Two independent researchers extracted raw data according to the inclusion criteria. If the two investigators generated different results, they would check the data again and have a discussion to make an agreement. If they could not reach an agreement, an expert was invited to the discussion. Data extracted from the selected articles included the first author’s name, year of publication, country of origin, ethnicity, subtype of acute leukemia, number of cases and controls, genotype frequency for cases and controls, and source of controls.

3. Statistical analysis
The risk of childhood acute leukemia that is associated with the polymorphisms of GSTM1 and GSTT1 genes were estimated for each study by odds ratio (OR), together with its 95% confidence interval (CI), respectively. Most studies evaluated GSTM1 and GSTT1 as presence/absence of gene deletion, so that meta-analysis of these polymorphisms were performed using a crude OR (null vs. present). A fixed-effect model using the Mantel-Haenszel method and a random-effects model using the DerSimonian and Laird method were used to combine values from studies. If the P value for heterogeneity was > 0.10 and I² < 50%, indicating an absence of heterogeneity between studies, we used the fixed-effect model to evaluate the summary ORs. In contrast, if the P value for heterogeneity was ≤ 0.10 or I² ≥ 50%, indicating a high extent of heterogeneity between studies, we used the random-effect model to evaluate the summary ORs.

Subgroup analyses were conducted by ethnicity (Asians, Blacks, and White), subtype of acute leukemia (ALL, AML and ANLL), number of cases and controls ( < 100 cases and < 100 controls, ≥ 100 cases and ≥ 100 controls) and control source (Hospital-based, Population-based). Possible publication bias was tested by Begg’s funnel plot and Egger’s test. All analyses were performed using STATA software, version 9.2 (STATA Corp., College Station, TX).

Results

1. Characteristics of Studies Analyzed
There were 117 articles relevant to searching strategy. The flow chart shown in Figure S1 summarizes the study selection process. Studies that had data on the different subtypes of acute leukemia or different ethnic groups were treated as independent studies. Thus, a total of 17 articles (26 independent case-control studies) including 3252 cases and 5024 controls were used in this meta-analysis. Publication dates ranged from 1997-2011. The characteristics of the selected studies are shown in Table 1 and Table 2. PRISMA checklist is shown in Table S1.

GSTM1 Polymorphism. A total of 26 studies were included in the meta-analysis with 3252 cases and 5024 controls. Cases consisted of 87.1% patients with ALL, 11.1% patients with AML and 1.8% patients with ANLL. Most of the controls (60.4%) were population-based participants.

GSTM1 Polymorphism. Totally, 24 studies met the inclusion criteria and were selected in this meta-analysis with 2934 cases and 4592 controls. Cases consisted of 85.7% patients with ALL, 12.3% patients with AML and 2.0% patients with ANLL. Most of the controls (63.3%) were population-based participants.
Table 1. Main characteristics of all studies of GSTM1 genotypes included in the meta-analysis.

| First author       | Year | Country | Ethnicity | Subtype of acute leukemia | Case | Age | Sex | Control | Age | Sex | Case | Control |
|--------------------|------|---------|-----------|---------------------------|------|-----|-----|---------|-----|-----|------|---------|
| Chen CL            | 1997 | USA     | White     | ALL                       | 163  | N/A | 85/78| 213     | 18-60| 111/102 | 73 (44.8) | 90 (55.2) | 99 (46.5) | 114 (53.5) | Population |
| Chen CL            | 1997 | USA     | Black     | ALL                       | 34   | N/A | 22/12| 203     | 18-60| 103/100 | 20 (58.8) | 14 (41.2) | 147 (72.4) | 56 (27.6) | Population |
| Krajinovic M       | 1999 | Canada  | White     | ALL                       | 174  | 1-21| 170/34| N/A     | N/A | N/A     | 61 (35.1) | 113 (64.9) | 148 (48.7) | 156 (51.3) | Population |
| Saadat I           | 2000 | Iran    | Asian     | ALL                       | 38   | 3-13| 26/12| 75      | 3-13 | 48/27   | 17 (44.7) | 21 (55.3) | 51 (68.0)  | 24 (32.0) | Population |
| Woo MH             | 2000 | USA     | White     | AML                      | 40   | N/A | 304/4| N/A     | N/A | N/A     | 25 (62.5) | 15 (37.5) | 69 (43.1) | 91 (56.9) | Hospital |
| Woo MH             | 2000 | USA     | Black     | AML                      | 7    | N/A | 38   | N/A     | N/A | N/A     | 2 (28.6)  | 5 (71.4)   | 24 (63.2) | 14 (36.8) | Hospital |
| Woo MH             | 2000 | USA     | White     | AML                      | 6    | N/A | 44   | N/A     | N/A | N/A     | 2 (33.3)  | 4 (66.7)   | 25 (56.8) | 19 (43.2) | Hospital |
| Davies SM          | 2000 | USA     | White     | AML                      | 232  | N/A | 153  | N/A     | N/A | N/A     | 168 (72.4)| 64 (27.6) | 106 (69.3)| 47 (30.7) | Population |
| Davies SM          | 2002 | USA     | Black     | ALL                      | 35   | N/A | 201  | N/A     | N/A | N/A     | 21 (60.0)| 14 (40.0) | 137 (68.2)| 64 (31.8) | Hospital |
| Alves S            | 2002 | Portugal| White     | ALL                      | 47   | N/A | 102  | N/A     | N/A | N/A     | 15 (31.9)| 32 (68.1) | 52 (51.0) | 50 (49.0) | Hospital |
| Krajinovic M       | 2002 | Canada  | White     | ALL                      | 269  | N/A | 301  | N/A     | N/A | N/A     | 118 (43.9)| 151 (56.1)| 160 (53.2)| 141 (46.8)| Hospital |
| Baita G            | 2003 | Turkey  | White     | ALL                      | 139  | 0.58-17| 96/48| 185     | 0.58-17| 120/65  | 62 (44.6) | 77 (55.4) | 84 (45.4) | 101 (54.6) | Population |
| Baita G            | 2003 | Turkey  | White     | ANLL                     | 31   | 1-17 | 19/14| 185     | 0.58-17| 120/65  | 12 (38.7) | 19 (61.3) | 84 (45.4) | 101 (54.6) | Population |
| Barnettee P        | 2004 | USA     | White     | ALL                      | 94   | N/A | 326  | N/A     | N/A | N/A     | 46 (48.9) | 48 (51.1) | 143 (43.9)| 183 (56.1)| Population |
| Canale R           | 2004 | Brazil  | White     | ALL                      | 113  | 0.22-18| 73/40| 221     | 18-58 | 159/62  | 65 (57.5) | 48 (42.5) | 120 (54.3)| 101 (45.7)| Population |
| Joseph T           | 2004 | India   | White     | ALL                      | 118  | 0-14 | 77/41| 118     | 0-14  | 77/41   | 70 (59.3) | 48 (40.7) | 89 (75.4)| 29 (24.6) | Hospital |
| Wang J             | 2004 | China   | Asian     | ALL                      | 67   | N/A | 146  | N/A     | N/A | N/A     | 16 (23.9)| 51 (76.1) | 69 (47.3) | 77 (52.7) | Population |
| Wang J             | 2004 | China   | Asian     | AML                      | 32   | N/A | 146  | N/A     | N/A | N/A     | 9 (28.1)  | 23 (71.9) | 69 (47.3) | 77 (52.7) | Population |
| Clavel J           | 2005 | France  | White     | ALL                      | 191  | < 15 | N/A  | 105     | N/A | N/A     | 57/48 (97.08)| 94 (49.2)| 55 (52.4)| 50 (47.6) | Hospital |
| Clavel J           | 2005 | France  | White     | AML                      | 28   | < 15 | N/A  | 105     | N/A | N/A     | 57/48 (97.08)| 94 (49.2)| 55 (52.4)| 50 (47.6) | Hospital |
| Pakakasama S       | 2005 | Thailand| Asian     | ALL                      | 107  | 0.83-14.7| 62/45| 320     | N/A | 165/155 | 31 (29.0) | 76 (71.0) | 129 (40.3)| 191 (59.7)| Population |
| Aydın-Saytoglu M   | 2006 | Turkey  | White     | ALL                      | 119  | N/A | 140  | 16-59  | 73/67 | 41 (34.5) | 78 (65.5) | 63 (45.0) | 77 (55.0) | Population |
| Aydın-Saytoglu M   | 2006 | Turkey  | White     | AML                      | 44   | N/A | 140  | 16-59  | 73/67 | 16 (36.4) | 28 (63.6) | 63 (45.0) | 77 (55.0) | Population |
| P ugllo S          | 2007 | Turkey  | White     | ALL                      | 323  | < 18 | N/A  | 384     | < 18 | N/A     | 171 (52.9)| 152 (47.1)| 184 (47.9)| 200 (52.1)| Hospital |
| Chan JY            | 2011 | Indonesia| Asian    | ALL                      | 185  | 0.03-14| 107/78| 177     | N/A | 104/73  | 43 (23.2)| 142 (76.8)| 55 (31.1)| 122 (68.9)| Population |

| Control source | Present | Null | Control | Present | Null |
|----------------|---------|------|---------|---------|------|
| Population     |         |      |         |         |      |
| Hospital       |         |      |         |         |      |

\* range of age (year); \^ sex male/female; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ANLL, acute non-lymphoblastic leukemia; NA, not available.

doi: 10.1371/journal.pone.0078810.t001
Table 2. Main characteristics of all studies of GSTT1 genotypes included in the meta-analysis.

| First author | Year | Country | Ethnicity | Subtype of acute leukemia | Case | Age a | Sex b | Control | Age a | Sex b | Case | Control | Control source |
|--------------|------|---------|-----------|---------------------------|------|-------|-------|---------|-------|-------|-------|---------|----------------|
| Chen CL      | 1997 | USA     | White     | ALL                       | 163  | N/A   | 85/78 | 213     | 18-60 | 111/102| 140  | 23 (14.1) | 181 (85.0) | 32 (15.0) | Population   |
| Chen CL      | 1997 | USA     | Black     | ALL                       | 34   | N/A   | 22/12 | 203     | 18-60 | 103/100| 22   | 12 (35.3) | 154 (75.9) | 49 (24.1) | Population   |
| Krajinovic M | 1999 | Canada  | White     | ALL                       | 176  | 1-21  | N/A   | 274     | N/A   | N/A   | 148  | 28 (15.9) | 227 (82.8) | 47 (17.2) | Population   |
| Woo MH       | 2000 | USA     | White     | AML                       | 40   | N/A   | N/A   | 160     | N/A   | N/A   | 33   | 7 (17.5)  | 138 (86.3) | 22 (13.8) | Hospital     |
| Woo MH       | 2000 | USA     | Black     | AML                       | 7    | N/A   | N/A   | 38      | N/A   | N/A   | 3    | 4 (57.1)  | 26 (68.4)  | 12 (31.6) | Hospital     |
| Davies SM    | 2000 | USA     | Hispanic  | AML                       | 6    | N/A   | N/A   | 44      | N/A   | N/A   | 4    | 2 (33.3)  | 36 (81.8)  | 8 (18.2)  | Hospital     |
| Davies SM    | 2002 | USA     | White     | ALL                       | 616  | N/A   | N/A   | 532     | N/A   | N/A   | 520  | 96 (15.6) | 445 (83.6) | 87 (16.4) | Hospital     |
| Davies SM    | 2002 | USA     | Black     | ALL                       | 35   | N/A   | N/A   | 201     | N/A   | N/A   | 29   | 6 (17.1)  | 145 (72.1) | 56 (27.9) | Hospital     |
| Alves S      | 2002 | Portugal| White     | ALL                       | 47   | N/A   | N/A   | 102     | N/A   | N/A   | 38   | 9 (19.1)  | 76 (74.5)  | 26 (25.5) | Population   |
| Baitsu G     | 2003 | Turkey  | White     | ALL                       | 139  | 0.58-17 | 96/48 | 185     | 0.58-17 | 120/65 | 110  | 29 (20.9) | 143 (77.3) | 42 (22.7) | Population   |
| Baitsu G     | 2003 | Turkey  | White     | ANLL                      | 31   | 1-17  | 19/14 | 185     | 0.58-17 | 120/65 | 29   | 2 (6.5)   | 143 (77.3) | 42 (22.7) | Population   |
| Barnettee P | 2004 | USA     | White     | ALL                       | 81   | N/A   | N/A   | 300     | N/A   | N/A   | 72   | 9 (11.1)  | 234 (78.0) | 66 (22.0) | Population   |
| Canaite R    | 2004 | Brazil  | White     | ALL                       | 113  | 0.33-18 | 73/40 | 221     | 18-58 | 159/62 | 88   | 25 (22.1) | 178 (80.5) | 43 (19.5) | Population   |
| Joseph T     | 2004 | India   | Asian     | ALL                       | 118  | 0-14  | 77/41 | 118     | 0-14  | 77/41 | 101  | 17 (14.4) | 108 (91.5) | 10 (8.5)  | Hospital     |
| Wang J       | 2004 | China   | Asian     | ALL                       | 67   | 0.83-18 | 44/23 | 146     | N/A   | N/A   | 25   | 42 (62.7) | 74 (50.7)  | 72 (49.3) | Population   |
| Wang J       | 2004 | China   | Asian     | AML                       | 32   | N/A   | N/A   | 146     | N/A   | N/A   | 13   | 19 (59.4) | 74 (50.3)  | 72 (49.3) | Population   |
| Clavel J     | 2005 | France  | White     | ALL                       | 191  | < 15  | N/A   | 105     | N/A   | N/A   | 149  | 42 (22.0) | 82 (78.1)  | 23 (21.9) | Hospital     |
| Clavel J     | 2005 | France  | White     | ANLL                      | 28   | < 15  | N/A   | 105     | N/A   | N/A   | 22   | 6 (21.4)  | 82 (78.1)  | 23 (21.9) | Hospital     |
| Pakakasama S | 2005 | Thailand| Asian     | ALL                       | 107  | 0.83-14.75 | 62/45 | 320     | N/A   | 165/155| 57   | 50 (46.7) | 198 (61.9) | 12 (38.1) | Population   |
| Aydin-Saytogi M | 2006 | Turkey | White     | ALL                       | 119  | N/A   | N/A   | 140     | 16-59 | 73/67 | 90   | 29 (24.4) | 111 (75.6) | 29 (20.7) | Population   |
| Aydin-Saytogi M | 2006 | Turkey | White     | AML                       | 44   | N/A   | N/A   | 140     | 16-59 | 73/67 | 38   | 6 (13.6)  | 111 (79.3) | 29 (20.7) | Population   |
| Piguollo S   | 2007 | Italy   | White     | ALL                       | 323  | < 18  | N/A   | 384     | < 18  | N/A   | 279  | 44 (19.8) | 315 (82.0) | 69 (18.0) | Hospital     |
| Chan JY      | 2011 | Indonesia| Asian    | ALL                       | 185  | 0.03-14 | 107/78 | 177     | N/A   | 104/73| 121  | 64 (34.6) | 128 (72.3) | 49 (27.7) | Population   |

a range of age (year); b male/female; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ANLL, acute non-lymphoblastic leukemia.

doi: 10.1371/journal.pone.0078810.t002
2. Meta-analysis of GSTM1 polymorphism and childhood acute leukemia

The evaluation of the association between GSTM1 polymorphism and childhood acute leukemia risk is summarized in Table 3. A significantly elevated association between the null genotype of GSTM1 polymorphism and childhood acute leukemia was found in all subjects (OR = 1.30; 95%CI, 1.11-1.51) (Figure 1). When stratified by ethnic groups, significantly elevated risks were observed in Asians (OR = 1.50; 95%CI, 1.17-1.93) (Figure 2), while the subgroup analysis by source of controls indicated no other single study influenced the pooled ORs materially.

3. Meta-analysis of GSTT1 polymorphism and childhood acute leukemia

The evaluations of the association of GSTT1 polymorphism and childhood acute leukemia are listed in Table 3. The null genotype of GSTT1 polymorphism was associated with a significantly increased risk of childhood acute leukemia in Asians (OR = 1.50; 95%CI, 1.17-1.93) (Figure 2), while the association was not observed in the overall analysis and subgroup analysis according to subtype of acute leukemia, number of cases and controls, and source of controls (Table 3).

4. Sensitive analysis

Sensitivity analyses were performed to determine whether modification of the inclusion criteria of the meta-analysis affected the final results. Although the sample size for cases and controls in 26 studies with a range from 6 to 616, the corresponding pooled ORs were not qualitatively altered with or without the study of small sample. Similarly, the sensitivity analysis indicated no other single study influenced the pooled ORs materially.

5. Publication Bias

Begg’s funnel plot and Egger’s test were performed to assess the publication bias of literatures. Figure S2 shows the funnel plot for the assessment of publication bias. For GSTM1, the shape of the funnel plot did not reveal any evidence of obvious asymmetry (P = 0.064) (Figure S2 A). However, the Egger’s test (P = 0.016) implied some evidence of publication bias. For GSTT1, both Begg’s test (P = 0.941) and Egger’s test (P = 0.991) did not suggest any evidence of publication bias (Figure S2 B).

Discussion

The present meta-analysis, including 3252 cases and 5024 controls from 26 case-control studies, exploring the association of GSTM1 and GSTT1 null polymorphisms with childhood acute leukemia risk. We demonstrated that the null polymorphism of GSTM1 was associated with a significant increase in overall childhood acute leukemia risk, whereas the null polymorphism of GSTT1 did not appear to have an overall
influence on the susceptibility of childhood acute leukemia. Furthermore, in the stratified analyses of \textit{GSTM1} null polymorphism, we found a significant influence on childhood acute leukemia risks in Asian and Black ethnic groups, ALL and population-based controls. However, we failed to find any significant relationships between \textit{GSTT1} null polymorphism and childhood acute leukemia risk except in group of Asian. The association of the \textit{GSTM1} null polymorphism but not the \textit{GSTT1} polymorphism with childhood acute leukemia may be an indication of substrate specificity of \textit{GSTM1} in metabolism of agents that are involved in the etiology of childhood acute leukemia.

To the best of our knowledge, we conducted by far the largest and most comprehensive meta-analysis for quantitative analyses between the roles of the \textit{GSTM1} and \textit{GSTT1} polymorphisms and childhood acute leukemia risk. The \textit{GSTM1} polymorphism is one of the most studied loci relating to childhood acute leukemia risk. The homozygous deletion resulting in functional loss of the \textit{GSTM1} enzyme has been implicated in the genesis of several cancers, including cervical neoplasia [15], colorectal cancer [34] and bladder cancer [35]. The present study suggests that the \textit{GSTM1} null genotype is associated with a higher risk of childhood acute leukemia. In 2005, a meta-analysis by Ye et al. [16], had reported no overall association of polymorphisms of \textit{GSTM1} and \textit{GSTT1} with childhood ALL risk, including 4721 subjects (about half the size of our population of 8276). A recent meta-analysis of 15 published case-control studies on the effect of these polymorphisms and risk of childhood ALL was performed [36]. One observation in the latter study, i.e. \textit{GSTM1} polymorphism but not \textit{GSTT1} polymorphism was associated with the risk of childhood ALL [36], is similar to us. However, no association of these polymorphisms with ANLL were investigated in both meta-analysis studies [16,36] and no association of these polymorphisms with AML were investigated in the latter study [34]. Inclusion in our meta-analysis of few recent studies and data from CBM database could be the reason for the differences in the inference.

Several factors must be considered in the design of a reliable case-control study in the future. Large sample size with adequate power is one of the most important factors. The choice of the control population is also considered to be a crucial factor because of the possible different exposure to environmental toxicants. Additionally, studies including information on the subtype of childhood acute leukemia are demanded to clarify the relationship between the GST polymorphisms and the subtypes of childhood acute leukemia.

There are some limitations should be acknowledged in this meta-analysis. Firstly, in the subgroup analyses of childhood acute leukemia, the number of AML and ANLL subgroups was relatively small, which don't have enough statistical power to explore the real association. Secondly, only three of the examined studies were performed in a Black population, so the ethnicity effect was not adequately investigated. Thirdly, our results were based on unadjusted estimates, while a more precise analysis should be conducted if all individual data was
available, which would allow for the adjustment by other co-
variants including age, gender, and environmental exposures. 
Fourthly, childhood acute leukemia is a muti-factorial disease 
that results from complex interactions between many genetic 
and environmental factors. It suggests that there will not be 
single gene or single environmental factor that has large effects 
on childhood acute leukemia susceptibility. In addition, as in 
most meta-analyses, publication bias must be considered 
because only published studies were included in the meta-
analysis.

In conclusion, this meta-analysis showed that an increased 
risk of childhood acute leukemia is associated with the null 
polymorphism of \textit{GSTM1}. It is necessary to conduct large 
and homogenic sample studies using standardized unbiased genotyping 
methods, homogeneous patients with childhood acute 
leukemia and well matched controls. Additionally, more studies 
or complete case-control studies, especially stratified by 
different ethnic background, environmental exposure or other 
risk factors, should be performed to clarify possible roles of 
\textit{GSTM1} and \textit{GSTT1} null polymorphisms in the pathogenesis of 
childhood acute leukemia in the future.

Supporting Information

Figure S1. Flow chart of study identification. Studies that 
had data on the different subtypes of acute leukemia (e.g., 
ALL, AML and ANLL) or different ethnic groups (e.g., Asians, 
Blacks and Whites) were treated as independent studies. Thus, 
a total of 26 studies were included in quantitative synthesis. 
(TIF)

Figure S2. Funnel plot analysis to detect publication bias. 
Each point represents a separate study for the indicated 
association. Funnel plot for \textit{GSTM1} (A) and \textit{GSTT1} (B) null 
polymorphisms in overall analysis. 
(TIF)

Table S1. PRISMA Checklist. 
(DOC)

Author Contributions

Conceived and designed the experiments: QT JL SZ WW. 
Performed the experiments: QT JL SZ BY. Analyzed the data: 
HS DW CL. Contributed reagents/materials/analysis tools: WW 
YX HD LH DC JS XW. Wrote the manuscript: WW DC.
References

1. Linet MS, Ries LA, Smith MA, Tarone RE, Devesa SS (1999) Cancer surveillance series: recent trends in childhood cancer incidence and mortality in the United States. J Natl Cancer Inst 91: 1051-1058. doi: 10.1093/jnci/91.12.1051. PubMed: 10379968.

2. Pui CH, Relling MV, Downing JR (2004) Acute lymphoblastic leukemia. N Engl J Med 350: 1535-1548. doi: 10.1056/NEJMr203001. PubMed: 15071128.

3. Pembile S, Schroeder KR, Spencer SR, Meyer DJ, Hallier E et al. (1994) Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 300 (1): 271-276. PubMed: 8198545.

4. Strange RC, Spiteri MA, Ramachandran S, Fryer AA (2001) Glutathione-S-transferase family of enzymes. Mutat Res 482: 21-26. doi:10.1016/S0165-2480(01)00183-7. PubMed: 11435245.

5. Pearson WR, Vorachek WR, Xu SJ, Berger R, Hart I et al. (1993) Identification of class-mu glutathione transferase genes GSTM1- GSTM5 on human chromosome 1p13. Am J Hum Genet 53: 220-233. PubMed: 8617495.

6. Webb G, Vaska V, Coggan M, Board P (1996) Chromosomal localization of polymorphism of the human theta class glutathione transferase (GSTT1). Genomics 33: 121-123. doi:10.1006/geno.1996.0167. PubMed: 8472315.

7. Strange RC, Fryer AA (1999) The glutathione S-transferases: influence of polymorphism on cancer susceptibility. IARC Sci Publ 231-249.

8. Gao LB, Pan XM, Li LJ, Liang WB, Bai P et al. (2011) Null genotypes of GSTA1 and GSTT1 contribute to risk of cervical neoplasia: an evidence-based meta-analysis. PLOS ONE 6: e20157. doi:10.1371/journal.pone.0020157. PubMed: 21629772.

9. Ye Z, Song H (2005) Glutathione S-transferase polymorphisms (GSTM1, GSTP1 and GSTT1) and the risk of acute leukemia: a systematic review and meta-analysis. Eur J Cancer Prev 14: 980-989. doi:10.1093/carcin/14.4.983. PubMed: 8959320.

10. Chen CL, Liu Q, Pui CH, Rivera GK, Sandlund JT et al. (1997) Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia. Blood 89: 1701-1707. PubMed: 9057653.

11. Krajnovic M, Labuda D, Richer C, Karimi S, Sinnett D (1999) Susceptibility to childhood acute lymphoblastic leukemia: influence of CYPIA1, CYPIB2, GSTM1, and GSTT1 genetic polymorphisms. Blood 93: 1496-1501. PubMed: 10025763.

12. Davies SM, Robison LL, Buckley JD, Randolf GA, Ross JA et al. (2000) Glutathione S-transferase polymorphisms in children with myeloid leukemia: a Children's Cancer Group study. Cancer Epidemiol Biomarkers Prev 9: 563-569. PubMed: 10956609.

13. Saadat I, Saadat M (2000) The glutathione S-transferase mu polymorphism and susceptibility to acute lymphocytic leukemia. Cancer Lett 158: 43-45. doi:10.1016/S0304-3835(00)00504-8. PubMed: 10940507.

14. Woo MH, Shuster JJ, Chen C, Bash RQ, Behm FG et al. (2000) Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies. Leukemia 14: 232-237. doi:10.1038/sj.leu.2401660. PubMed: 10673738.

15. Alves S, Amorim A, Ferreira F, Norton L, Prata MJ (2002) The GSTM1 and GSTT1 genotypes and susceptibility to acute lymphoblastic leukemia in children from north Portugal. Leukemia 16: 1565-1567. doi:10.1038/sj.leu.2402543. PubMed: 12145701.

16. Davies SM, Bhatia S, Ross JA, Kiffmeyer WR, Gaynon PS et al. (2002) Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood 100: 67-71. doi:10.1182/blood.V100.1.0.67. PubMed: 12070010.

17. Krajnovic M, Labuda D, Sinnett D (2002) Glutathione S-transferase S1 genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukemia. Blood 100: 655-658. doi:10.1182/blood.V100.1.655. PubMed: 12439226.

18. Balta G, Yuksek O, Ozyurek E, Eturm U, Hisconnez G et al. (2003) Characterization of MTHFR, GSTM1, GSTT1, GSTP1, and CYP1A1 genotypes in childhood acute leukemia. Am J Hematol 73: 154-160. doi:10.1002/ajh.10339. PubMed: 12387265.

19. Parmette P, Scholl R, Blandford M, Ballard L, Tsiodrow A et al. (2004) High-throughput detection of glutathione s-transferase polymorphic alleles in a pediatric cancer population. Cancer Epidemiol Biomarkers Prev 13: 304-313. doi:10.1158/1055-9965.EPI-03-0178. PubMed: 14973099.

20. Canalle R, Burim RV, Tone LG, Takahashi CS (2004) Genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukemia. Environ Mol Mutagen 43: 100-109. doi:10.1002/em.20003. PubMed: 14991750.

21. Joseph T, Kusumakumary P, Chacko P, Abraham A, Radhakrishna Pillai M (2004) Genetic polymorphism of CYP1A1, CYP2D6, GSTM1 and GSTT1 and susceptibility to acute lymphoblastic leukaemia in Indian children. Pediatri Blood Cancer 43: 560-567. doi:10.1002/bpc.20074. PubMed: 15382273.

22. Clavel J, Bellot S, Reboissou S, Ménégax F, Feunteun J et al. (2005) Childhood leukemia, polymorphisms of metabolism enzyme genes, and interactions with maternal tobacco, coffee and alcohol consumption during pregnancy. Eur J Cancer Prev 14: 531-540. doi:10.1097/00008571-200506000-00007. PubMed: 16284498.

23. Pakakasama S, Mukda E, Sasanakul W, Kadegasem P, Udomsuppayakul U et al. (2005) Polymorphisms of drug-metabolizing enzymes and risk of childhood acute lymphoblastic leukemia. Am J Hematol 79: 202-205. doi:10.1002/ajh.20404. PubMed: 15981231.

24. Aoyama S, Sanyt-Smigielska M, Hanajima N, Okumura H et al. (2008) Role of CYP2D6, CYP1A1, CYP2E1, GSTT1, and GSTM1 genes in the susceptibility to acute leukemias. Am J Hematol 81: 162-170. doi:10.1002/ajh.10339. PubMed: 18493615.

25. Figlio S, Haupt R, Dufour C, Di Michele P, Valsecchi MG et al. (2007) Are genotypes of glutathione S-transferase superfamily a risk factor for childhood acute lymphoblastic leukemia? Results of an Italian case-control study. Leukemia 21: 1122-1124. PubMed: 17315021.

26. Chan YJ, Ugrasena DG, Lum DW, Lu Y, Yeoh AE (2011) Xenobiotic and folate pathway gene polymorphisms and risk of childhood acute lymphoblastic leukemia. J Natl Cancer Inst 103: 1613-1621. doi:10.1093/jnci/djr296. PubMed: 22027535.

27. Garcia-Closas M, Malats N, Silverman D, Dossemei M, Kogevinas M et al. (2005) NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 366: 549-559. doi:10.1016/S0140-6736(05)67137-1. PubMed: 16112301.

28. Vijayakrishnan J, Houlston RS (2010) Candidate gene association studies and risk of childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. Haematologica 95: 1405-1414. doi:10.3324/haematol.2010.022095. PubMed: 20511665.